This ambitious phase 1 study builds on the authors 2024 experience in Sci Tran Med with positive results with autologous transplantation of P63 progenitor cells in patients with COPD. The current ...
This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...
2019). In August 2023, the company began a Phase 1 open-label safety study of direct brain injection of purified and expanded adipose-derived stem cells in people with AD. Nine patients in three ...
Stem cell therapy has come a long way since its early days. As an athlete who has undergone it twice, I know that the ...
"Since the process of stem cell transplantation damages the gut microbiome, we want to see if FMT will help restore microbial diversity and promote the beneficial bacterial species that support a ...
Many degenerative diseases, like Parkinson’s disease, multiple sclerosis, or heart failure, have always been concerning when it comes to ...
Jan. 31, 2025 — Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its frontline defenders -- T cells -- lose their ability to ...
We have to give very intensive chemotherapy and/or radiation before we can even get the stem cells. We’re actually making patients much sicker and much worse before the transplant process. It really ...
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the ...
Since the process of stem cell transplantation damages the gut microbiome, we want to see if FMT will help restore microbial diversity and promote the beneficial bacterial species that support a ...
Stem-cell research is the area of research that studies the properties of stem cells and their potential use in medicine. As stem cells are the source of all tissues, understanding their ...